Entero Therapeutics, Inc.

Entero Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing targeted, orally delivered therapies for gastrointestinal (GI) diseases. At the core of its research are three proprietary technologies. Latiglutenase is an oral biotherapeutic designed to disrupt gluten and lessen symptoms of celiac disease. Capeserod acts as a selective 5-HT4 receptor partial agonist, being explored for treating various GI conditions, including gastroparesis. Adrulipase is a recombinant lipase enzyme aimed at facilitating lipid and nutrient digestion in patients suffering from exocrine pancreatic insufficiency, such as those with cystic fibrosis and chronic pancreatitis. Entero Therapeutics` program pipeline addresses multiple GI-related conditions, including autoimmune disorders and nutrition-related diseases, targeting specific patient populations affected by these ailments.